No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line
Neurizon Finds Positive Results for Lead Drug in 3D Brain Model Study
ASX Biggest Gainers
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate With Two Studies; Shares Fall 5%
Investing in Neurizon Therapeutics (ASX:NUZ) Five Years Ago Would Have Delivered You a 54% Gain
Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024